Insight Molecular Diagnostics (IMDX) Enterprise Value: 2020-2025
Historic Enterprise Value for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $75.6 million.
- Insight Molecular Diagnostics' Enterprise Value rose 117.84% to $75.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 12.11%. This contributed to the annual value of $31.4 million for FY2024, which is 135.99% up from last year.
- Per Insight Molecular Diagnostics' latest filing, its Enterprise Value stood at $75.6 million for Q3 2025, which was up 21.78% from $62.1 million recorded in Q2 2025.
- Insight Molecular Diagnostics' Enterprise Value's 5-year high stood at $468.0 million during Q2 2021, with a 5-year trough of $11.5 million in Q3 2023.
- In the last 3 years, Insight Molecular Diagnostics' Enterprise Value had a median value of $31.4 million in 2024 and averaged $36.0 million.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Enterprise Value spiked by 320.67% in 2021, and later crashed by 87.57% in 2022.
- Over the past 5 years, Insight Molecular Diagnostics' Enterprise Value (Quarterly) stood at $166.3 million in 2021, then plummeted by 87.57% to $20.7 million in 2022, then crashed by 35.55% to $13.3 million in 2023, then surged by 135.99% to $31.4 million in 2024, then surged by 117.84% to $75.6 million in 2025.
- Its last three reported values are $75.6 million in Q3 2025, $62.1 million for Q2 2025, and $56.5 million during Q1 2025.